Researchers block cancer-related genes with small interfering peptides

February 19, 2014 by Anke Van Eekelen
Human breast cancer cells dividing. Credit: Dr David Becker, Wellcome Images

Synthetic peptides are showing promise in their ability to prevent out of control tumour growth—and according to researchers are fast becoming the core of new therapeutic opportunities for cancer treatment.

Researchers are engineering small interfering peptides (ipeps) to block the function of cancer-related genes to disrupt intracellular processes in .

This strategy targets epigenetic mutations or biological alterations, which are dynamic chemical changes in the DNA structure at the position of tumour genes.

IPeps are designed to reverse the epigenetic state of cancer cells back to normal.

Their effectiveness in was recently shown in Oncogene by Dr Pilar Blancafort, head of the Cancer Epigenetics Group at UWA, and her collaborators at the University of North Carolina at Chapel Hill, USA.

The researchers showed that a new type of synthetic iPeps – designed to target transcription factor Engrailed 1 (EN1) in triple negative cells – could modify the epigenetic status of the EN1 gene.

EN1-iPeps blocked the expression of this transcription factor in experimental tumor cells in a dish. The absence of EN-1 then activated those intracellular processes that allow normal cells to die. As a result, it stopped the uncontrollable growth.

"We hit a transcription factor that really should not have been there," Dr Blancafort says. EN1 is a brain-specific factor, normally not expressed in breast tissue.

EN1 expression contributes to the stem cell-like profile of the triple negative , known for their DNA instability and rapidly acquired resistance to chemotherapy—currently the only treatment option.

"Many people understand that cancer has a genetic base, meaning that mutations are driving cancer, but there is now also mounting evidence that the microenvironment of a tumour can modulate its outcome," Dr Blancafort says.

Epigenetic changes in cancer cells, like the level of methylation of specific DNA sites, tend to be reversible. Dr Blancafort says such changes should be seen as new targets for intervention.

She says cancers with poor clinical outcome may benefit most from combining iPeps use with conventional chemotherapy.

This way, the modifying effect of iPeps on the epigenetic profile of the cancer could prevent drug resistance and possibly 'oncogenic addiction'.

"Unlike healthy cells, [oncogenetically addicted] tumour cells show so much plasticity. You hit them at the core, but they still adapt and come up with another solution to survive."

Dr Blancafort, a Spanish cancer geneticist, arrived in WA last year and has since secured research funding from various federal, state and local organisations to move from cell culture studies to safe iPeps use in animal and patient models.

Related Stories

Linking risk factors and disease origins in breast cancer

November 20, 2013

Researchers from the Geisel School of Medicine at Dartmouth have found that epigenetic changes to DNA are associated with aging in disease-free breast tissues and are further altered in breast tumors. Epigenetic changes describe ...

Team finds potential cause for deadly breast cancer relapse

November 25, 2013

Researchers at the UNC School of Medicine, working with cell lines in a lab, have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and UNC scientists are developing ways ...

New drug candidate starves dormant cancer cells

February 18, 2014

In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starvation. ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

Lymphomas tied to metabolic disruption

July 17, 2015

Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio have found evidence that directly links disrupted metabolism (energy production in cells) to a common and often fatal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.